What Have We Learned? Best Practices In The Management of DME Part 2 Live

What Have We Learned Best Practices In The Management of DME Part 2 Live
Media formats available:
Details
Presenters
  • Overview

    This webinar will focus on relevant and timely discussions about treating patients with diabetic retinopathy and diabetic macular edema. The COVID-19 pandemic has resulted in additional challenges for both patients and retina specialists. The esteemed panel, chaired by Sophie Bakri, MD, will examine clinical trial data and share their expertise on treatment options during these unprecedented times, methods for implementing treatment, and the role of inflammation, among other topics.Grantor Statement Supported by an independent educational grant from Allergan.
  • Learning Objectives

    • Identify the role of inflammation in patients with DME and DR.
    • Implement treatment regimens for patients with DME and DR.
    • Through real world and post hoc analyses, identify the drawbacks to current use of anti-VEGFs in DME.
    • Differentiate steroids in the management of DME while implementing strategies for treatment and patient outcomes.
  • Accreditation

    Provided by Evolve Medical EducationAccreditation Statement Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation Statement Evolve designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • Participation Method

    In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

     

    Course Viewing Requirements

    Supported Browsers:

    Internet Explorer 11 for Windows

    Edge (recent versions; Chromium-based) for Windows

    Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux

    Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux

    Safari (recent versions) for Mac OSX, or iOS

    Hardware Requirements:

    4GB+ RAM

    Recommended internet speed 5Mbps+

  • Faculty and Disclosures

    DISCLOSURE POLICY
    It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

    Faculty:Sophie J. Bakri, MD Program Chair Professor of Ophthalmology Mayo Clinic Rochester, Minnesota   Peter K. Kaiser, MD Chaney Family Endowed Chair of Ophthalmology Research Cole Eye Institute Cleveland, Ohio  
    Baruch D. Kuppermann, MD, PhD Roger F. Steinert Professor and Chair Department of Ophthalmology School of Medicine Director, Gavin Herbert Eye Institute Professor, Department of Biomedical Engineering The Henry Samueli School of Engineering University of California, Irvine Irvine, California
     
    Christina Y. Weng, MD, MBAAssociate Professor of Ophthalmology Baylor College of Medicine Houston, Texas
      DISCLOSURE POLICY It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity. The following faculty/staff members have the following financial relationships with commercial interests:Sophie J. Bakri, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Advernum, Alimera Sciences, Allegro, Allergan, EyePoint, Kala Pharmaceuticals, Oxurion, Novartis, and Roche.  Grant/Research Support: Lowy Medical Foundation and NIH. Peter Kaiser, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Aerpio, Alcon, Allegro Ophthalmics, Allergan, Bayer, Bausch + Lomb, Biogen Idec, Boerenger Ingelheim, Clearside Biomedical, Eyevensys, Galecto, Galimedix, iRenix, jCyte,Kanghong Biotech, Kodiak Sciences, NGM Biopharmaceuticals, Novartis, Omeros, Ophthea, Ophthotech, Oxurion, Regeneron Pharmaceuticals, RegenexBio, Retinal Sciences, Santen, SciFluor, Shire, Stealth Biotherapeutics, and Verena. Grant/Research Support: National Eye Institute, National institute of Health and Research to Prevent Blindness. Speaker’s Bureau: Allegro Ophthalmics, Clearside Biomedical, Ophthotech, Retinal Sciences and Verena. Baruch D. Kuppermann, MD, PHD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allegro, Allergan, Aprea, Cell Care, Dose, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics, IVERIC bio/Ophthotech,  jCyte, Novartis, Oculis, Regeneron, Revana, Ripple Therapeutics, and Theravance Biopharma. Grants/Research Support: Alcon, Allegro, Allergan, Apellis, Clearside, Genentech, GSK, Ionis, IVERIC bio, jCyte, Novartis, and Regeneron. Christina Y. Weng, MD, MBA, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Alimera Sciences, Allergan and Novartis.   The Evolve staff and planners have no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.  
  • Disclaimer

    OFF-LABEL STATEMENT This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMER The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Allergan.
  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Register

We're glad to see you're enjoying Evolve Medical Education…
but how about a more personalized experience?

Register for free